Targeting syndecan shedding in cancer

Extracellular Matrix: Pathobiology and Signaling

Volumn , Issue , 2012, Pages 802-812

  Sanderson, Ralph D ^a   Couchman, John R ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877713078     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (63)

1. Andersen, N. F., Standal, T., Nielsen, J. L., et al. (2005). Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 128, 210-217.
2. Bass, M. D., Morgan, M. R., and Humphries, M. J. (2009). Syndecans shed their reputation as inert molecules. Sci Signal 2, pe18.
3. Bayer-Garner, I. B., Sanderson, R. D., Dhodapkar, M. V., Owens, R. B., and Wilson, C. S. (2001). Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14, 1052-1058.
4. Beauvais, D. M., Ell, B. J., McWhorter, A. R., and Rapraeger, A. C. (2009). Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 206, 691-705.
5. Bondeson, J., Wainwright, S., Hughes, C., and Caterson, B. (2008). The regulation of ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol 26, 139-145.
6. Borset, M., Hjorth-Hansen, H., Seidel, C., Sundan, A., and Waage, A. (1996). Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 88, 3998-4004.
7. Brule, S., Charnaux, N., Sutton, A., et al. (2006). The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 16, 488-501.
8. Buczek-Thomas, J. A., Hsia, E., Rich, C. B., Foster, J. A., and Nugent, M. A. (2008). Inhibition of histone acetyltransferase by glycosaminoglycans. J Cell Biochem 105, 108-120.
9. Bussolino, F., Di Renzo, M. F., Ziche, M., et al. (1992). Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119, 629-641.
10. Chen, L., and Sanderson, R. D. (2009). Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One 4, e4947.
11. Choi, S., Lee, H., Choi, J. R., and Oh, E. S. (2010). Shedding; towards a new paradigm of syndecan function in cancer. BMB Rep 43, 305-310.
12. Couchman, J. R. (2010). Transmembrane signalling proteoglycans. Annu Rev Cell Dev Biol 26, 89-114.
13. Derksen, P. W., Keehnen, R. M., Evers, L. M., van Oers, M. H., Spaargaren, M., and Pals, S. T. (2002). Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signalling in multiple myeloma. Blood 99, 1405-1410.
14. Dews, I. C., and Mackenzie, K. R. (2007). Transmembrane domains of the syndecan family of growth factor coreceptors display a hierarchy of homotypic and heterotypic interactions. Proc Natl Acad Sci U S A 104, 20782-20787.
15. Dhodapkar, M. V., Kelly, T., Theus, A., Athota, A. B., Barlogie, B., and Sanderson, R. D. (1997). Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol 99, 368-371.
16. Ding, K., Lopez-Burks, M., Sanchez-Duran, J. A., Korc, M., and Lander, A. D. (2005). Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol 171, 729-738.
17. Echtermeyer, F., Bertrand, J., Dreier, R., et al. (2009). Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med 15, 1072-1076.
18. Edwards, D. R., Handsley, M. M., and Pennington, C. J. (2008). The ADAM metalloproteinases. Mol Aspects Med 29, 258-289.
19. Elenius, V., Gotte, M., Reizes, O., Elenius, K., and Bernfield, M. (2004). Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1. J Biol Chem 279, 41928-41935.
20. Endo, K., Takino, T., Miyamori, H., et al. (2003). Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 278, 40764-40770.
21. Fitzgerald, M. L., Wang, Z., Park, P. W., Murphy, G., and Bernfield, M. (2000). Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signalling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148, 811-824.
22. Hov, H., Tian, E., Holien, T., et al. (2009). c-Met signalling promotes IL-6-induced myeloma cell proliferation. Eur J Haematol 82, 277-287.
23. Kainulainen, V., Wang, H., Schick, C., and Bernfield, M. (1998). Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J Biol Chem 273, 11563-11569.
24. Kelly, T., Miao, H. Q., Yang, Y., et al. (2003). High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 63, 8749-8756.
25. Kelly, T., Suva, L. J., Nicks, K. M., MacLeod, V., and Sanderson, R. D. (2010). Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. J Bone Miner Res 25, 1295-1304.
26. Khotskaya, Y. B., Dai, Y., Ritchie, J. P., et al. (2009). Syndecan-1 is required for robust growth, vascularization and metastasis of myeloma tumors in vivo. J Biol Chem 284, 26085-26095.
27. Leco, K. J., Khokha, R., Pavloff, N., Hawkes, S. P., and Edwards, D. R. (1994). Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269, 9352-9360.
28. Lendorf, M. E., Manon-Jensen, T., Kronqvist, P., Multhaupt, H. A. B., and Couchman, J. R. (2011). Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J Histochem Cytochem 59, 615-629.
29. Li, Q., Park, P. W., Wilson, C. L., and Parks, W. (2002). Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111, 635-646.
30. Liu, C. J., Lee, P. H., Lin, D. Y., et al. (2009). Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 50, 958-968.
31. Liu, D., Shriver, Z., Venkataraman, G., El Shabrawi, Y., and Sasisekharan, R. (2002). Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumour growth and metastasis. Proc Natl Acad Sci U S A 99, 568-573.
32. Maeda, T., Desouky, J., and Friedl, A. (2006). Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumour angiogenesis. Oncogene 25, 1408-1412.
33. Manon-Jensen, T., Itoh, Y., and Couchman, J. R. (2010). Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 277, 3876-3889.
34. Mundy, G. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2, 584-593.
35. Munesue, S., Yoshitomi, Y., Kusano, Y., et al. (2007). A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 282, 28164-28174.
36. Nagase, H., Visse, R., and Murphy, G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69, 562-573.
37. Naggi, A., Casu, B., Perez, M., et al. (2005). Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 280, 12103-12113.
38. Pruessmeyer, J., Martin, C., Hess, F. M., et al. (2010). A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells. J Biol Chem 285, 555-564.
39. Purushothaman, A., Chen, L., Yang, Y., and Sanderson, R. D. (2008). Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 283, 32628-32636.
40. Purushothaman, A., Hurst, D. R., Pisano, C., Mizumoto, S., Sugahara, K., and Sanderson, R. D. (2011). Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem 286, 30377-30383.
41. Purushothaman, A., Uyama, T., Kobayashi, F., et al. (2010). Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115, 2449-2457.
42. Ramani, V. C., Yang, Y., Ren, Y., Nan, L., and Sanderson, R. D. (2011). Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem 286, 6490-6499.
43. Ramani, V. C., Pruett, P. S., Thompson, C. A., DeLucas, L. D., and Sanderson, R. D. (2012). Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J Biol Chem 287, 9952-9961.
44. Ritchie, J. P., Ramani, V. C., Ren, Y., et al. (2011). SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17, 1382-1393.
45. Rodriguez-Manzaneque, J. C., Carpizo, D., Plaza-Calonge Mdel, C., et al. (2009) Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion. Int J Biochem Cell Biol 41, 800-810.
46. Saftig, P., and Reiss, K. (2011). The "a disintegrin and metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol 90, 527-535.
47. Schmidt, A., Echtermeyer, F., Alozie, A., Brands, K., and Buddecke, E. (2005). Plasmin and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds. J Biol Chem 280, 34441-34446.
48. Schulz, J. G., Annaert, W., Vandekerckhove, J., Zimmermann, P., De Strooper, B., and David, G. (2003). Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase-dependent and modulates cytosolic signalling. J Biol Chem 278, 48651-48657.
49. Seidel, C., Borset, M., Hjertner, O., et al. (2000a). High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 96, 3139-3146.
50. Seidel, C., Sundan, A., Hjorth, M., et al. (2000b). Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95, 388-392.
51. Shafat, I., Ben-Arush, M. W., Issakov, J., et al. (2010). Preclinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med 15, 1857-1864.
52. Stanley, M. J., Stanley, M. W., Sanderson, R. D., and Zera, R. (1999). Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 112, 377-383.
53. Su, G., Blaine, S. A., Qiao, D., and Friedl, A. (2007). Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J Biol Chem 282, 14906-14915.
54. Tsanou, E., Ioachim, E., Briasoulis, E., et al. (2004). Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components. J Exp Clin Cancer Res 23, 641-650.
55. Wang, Z., Gotte, M., Bernfield, M., and Reizes, O. (2005). Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site. Biochemistry 44, 12355-12361.
56. Whiteford, J. R., Behrends, V., Kirby, H., Kusche-Gullberg, M., Muramatsu, T., and Couchman, J. R. (2007). Syndecans promote integrin-mediated adhesion of mesenchymal cells in two distinct pathways. Exp Cell Res 313, 3902-3913.
57. Yang, Y., Macleod, V., Bendre, M., et al. (2005). Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 105, 1303-1309.
58. Yang, Y., MacLeod, V., Dai, Y., et al. (2007a). The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110, 2041-2048.
59. Yang, Y., Macleod, V., Miao, H. Q., et al. (2007b). Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282, 13326-13333.
60. Yang, Y., Yaccoby, S., Liu, W., et al. (2002). Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100, 610-617.
61. Yu, W. H., and Woessner, J. F. (2001). Heparin-enhanced zymographic detection of matrilysin and collagenases. Anal Biochem 293, 38-42.
62. Yu, W. H., Yu, S., Meng, Q., Brew, K., and Woessner, J. F. (2000). TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 275, 31226-31232.
63. Zhou, H., Roy, S., Cochran, E., et al. (2011). M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One 6, e21106.